JFBR vs TBPH

For growth investors, Jeffs' Brands Ltd (JFBR) is the stronger pick with 36.

8% revenue growth year-over-year, versus 12. 1% for Theravance Biopharma, Inc. (TBPH). Analysts rate Theravance Biopharma, Inc. (TBPH) a "Hold" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Theravance Biopharma, Inc.

(TBPH) delivered a total return of -13. 8%, compared to -100. 0% for Jeffs' Brands Ltd (JFBR). Over 10 years, the gap is even starker: TBPH returned -8. 6% versus JFBR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jeffs' Brands Ltd (JFBR) is the lower-risk stock at 0.

36β versus Theravance Biopharma, Inc. 's 0. 89β — meaning TBPH is approximately 146% more volatile than JFBR relative to the S&P 500. On balance sheet safety, Jeffs' Brands Ltd (JFBR) carries a lower debt/equity ratio of 5% versus 28% for Theravance Biopharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Jeffs' Brands Ltd (JFBR) is pulling ahead at 36.

8% versus 12. 1% for Theravance Biopharma, Inc. (TBPH). On earnings-per-share growth, the picture is similar: Jeffs' Brands Ltd grew EPS 63. 9% year-over-year, compared to -15. 0% for Theravance Biopharma, Inc.. Over a 3-year CAGR, JFBR leads at 28. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Jeffs' Brands Ltd (JFBR) is the more profitable company, earning -57.

0% net margin versus -87. 6% for Theravance Biopharma, Inc. — meaning it keeps -57. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JFBR leads at -45. 3% versus -72. 9% for TBPH. At the gross margin level — before operating expenses — TBPH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Jeffs' Brands Ltd (JFBR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

36)). Both have compounded well over 10 years (JFBR: -100. 0%, TBPH: -8. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JFBR (Consumer Cyclical) and TBPH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JFBR is a small-cap high-growth stock; TBPH is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.